4
Feb
2015
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
The Merck Exodus: Where Are the Talented People Going?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
Implications of the Biotech Boom on the Business and Science of R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2015
Welcome to the Timmerman Report
Welcome to a new adventure in biotech journalism. After a year in the writer’s cave, the Lee Hood book is well on its way. It can now be converted into a nights and weekends project as I come down the stretch with editing. It has been a wonderful reporting challenge putting such a complicated life under the microscope. But I... Read More